Published in Oncoimmunology on January 01, 2013
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors. Oncol Lett (2014) 0.83
CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer. Oncotarget (2015) 0.78
Follicular helper T cells in rheumatoid arthritis. Clin Rheumatol (2015) 0.77
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Mol Cancer (2014) 0.76
B Cell Anomalies in Autoimmune Retinopathy (AIR). Invest Ophthalmol Vis Sci (2017) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol (2005) 1.38
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res (2004) 1.15
Platelet activation in patients with advanced gastric cancer. Neoplasma (2010) 1.05
Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J (2006) 1.00
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Kalirin, a multifunctional Rho guanine nucleotide exchange factor, is necessary for maintenance of hippocampal pyramidal neuron dendrites and dendritic spines. J Neurosci (2003) 1.60
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Prevalence and determinants of metabolic syndrome among women in Chinese rural areas. PLoS One (2012) 1.20
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) (2008) 1.13
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 1.07
Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol (2010) 1.04
Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther (2009) 1.03
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer (2006) 1.02
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol (2013) 1.01
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther (2010) 0.99
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med (2012) 0.98
Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis Rheum (2010) 0.97
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg Med Chem Lett (2004) 0.97
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther (2007) 0.97
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res (2005) 0.96
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol (2014) 0.94
Induction of lamellipodia by Kalirin does not require its guanine nucleotide exchange factor activity. Exp Cell Res (2005) 0.93
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunol Immunother (2014) 0.93
Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology (2013) 0.93
Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res (2013) 0.92
Mutations in NPHS2 in sporadic steroid-resistant nephrotic syndrome in Chinese children. Nephrol Dial Transplant (2005) 0.92
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A (2014) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol Immunother (2013) 0.90
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther (2003) 0.90
Reactions of Chinese adults to warning labels on cigarette packages: a survey in Jiangsu Province. BMC Public Health (2011) 0.89
PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2006) 0.88
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol Immunother (2009) 0.88
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer (2010) 0.88
TRICOM vector based cancer vaccines. Curr Pharm Des (2006) 0.87
Diethyl 4,4'-(diazenediyl)dibenzoate. Acta Crystallogr Sect E Struct Rep Online (2011) 0.87
Primer design and marker clustering for multiplex SNP-IT primer extension genotyping assay using statistical modeling. Bioinformatics (2004) 0.86
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
The effect of fresh bone marrow cells on reconstruction of mouse calvarial defect combined with calvarial osteoprogenitor cells and collagen-apatite scaffold. J Tissue Eng Regen Med (2012) 0.86
Therapeutic vaccines for prostate cancer. Oncologist (2006) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
The use of bisphosphonates in cancer patients. Acta Oncol (2007) 0.85
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. Clin Genitourin Cancer (2007) 0.85
Hepcidin, anaemia, and prostate cancer. BJU Int (2011) 0.85
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer (2007) 0.84
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer (2013) 0.84
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Bone tissue engineering with a collagen-hydroxyapatite scaffold and culture expanded bone marrow stromal cells. J Biomed Mater Res B Appl Biomater (2014) 0.84
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83